In the News
Press Releases
Alzheon Appoints David Nikodem, Ph.D., to Board of Directors
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that David Nikodem, Ph.D., has joined [...]
Alzheon Announces Patent Issuance in Japan for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., September 5, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the Japan Patent Office [...]
Alzheon Announces Notice of Allowance for U.S. Patent for its Lead Drug Candidate ALZ-801 in Clinical Development for Alzheimer’s Disease
LEXINGTON, Mass., April 15, 2014 -- Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the United States Patent [...]
Alzheon Announces Nomination by Industry Leaders for The Most Promising Company competition at the Personalized Medicine World Conference
LEXINGTON, Mass., January 16, 2014 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, today announced that it has been nominated [...]
Alzheon Launches with Veteran Team and Funding to Accelerate Drug Development in Alzheimer’s Disease and Other Neurodegenerative Disorders
Company Obtains Exclusive License to Novel Clinical Alzheimer’s Disease Drug Candidate and Platform Developed by BELLUS Health Company to Advance ALZ-801 into Phase 2 Clinical Study [...]